Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of NEXIEN BIOPHARMA, INC. from 30 Jun 2018 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
NEXIEN BIOPHARMA, INC. quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 30 Jun 2018 to 30 Sep 2024.
  • NEXIEN BIOPHARMA, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 30 Sep 2024 was $770.
  • NEXIEN BIOPHARMA, INC. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $30,964, a 62% increase from 2023.
  • NEXIEN BIOPHARMA, INC. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $81,751, a 183% decline from 2022.
  • NEXIEN BIOPHARMA, INC. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was $98,857, a 1263% increase from 2021.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)

NEXIEN BIOPHARMA, INC. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $770 +$17,853 01 Jul 2024 30 Sep 2024 10-Q 18 Nov 2024 2025 Q1
Q3 2023 $17,083 -$1,333 -8.5% 01 Jul 2023 30 Sep 2023 10-Q 18 Nov 2024 2025 Q1
Q3 2022 $15,750 -$1,403 -9.8% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2024 Q1
Q3 2021 $14,347 -$11,763 -455% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2023 Q1
Q3 2020 $2,584 +$72,951 +97% 01 Jul 2020 30 Sep 2020 10-Q 22 Nov 2021 2022 Q1
Q3 2019 $75,535 +$170,109 +69% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2021 Q1
Q3 2018 $245,644 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2020 Q1

NEXIEN BIOPHARMA, INC. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $30,964 +$50,787 +62% 01 Jul 2023 30 Jun 2024 10-K 22 Oct 2024 2024 FY
2023 $81,751 -$180,608 -183% 01 Jul 2022 30 Jun 2023 10-K 22 Oct 2024 2024 FY
2022 $98,857 +$91,602 +1263% 01 Jul 2021 30 Jun 2022 10-K 28 Sep 2023 2023 FY
2021 $7,255 +$142,825 01 Jul 2020 30 Jun 2021 10-K 28 Sep 2022 2022 FY
2020 $135,570 +$537,813 +80% 01 Jul 2019 30 Jun 2020 10-K 12 Oct 2021 2021 FY
2019 $673,383 -$1,250,344 -217% 01 Jul 2018 30 Jun 2019 10-K 28 Sep 2020 2020 FY
2018 $576,961 01 Jul 2017 30 Jun 2018 10-K 30 Sep 2019 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.